Therefore, the miR-129/Bcl-2 axis mediated the SAHA sensitivity in NPC-tolerant tumor in vivo, which might provide a novel therapeutic strategy to overcome HDACi tolerance in NPC cancer. This evidence concerns the gene BCL2 and neoplasm.